Comparing the current results to its competitors, Clearmind Medicine Inc reported Revenue increase in the 1 quarter 2025 by 0 % year on year. The revenue growth was below Clearmind Medicine Inc's competitors' average revenue growth of 18.47 %, achieved in the same quarter.
Clearmind Medicine Inc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 16.64 %
Clearmind Medicine Inc's Comment on Competition and Industry Peers
The company operates in a highly competitive pharmaceutical industry characterized by rapid technological and scientific advancements. Competitors may obtain regulatory approval earlier or develop therapies that are safer, more advanced, or more effective. Competition affects both current and future programs the company may develop or commercialize. Market acceptance of the company's products depends on regulatory approvals, the competitive landscape, demonstrated safety and efficacy, strategic agreements, marketing efforts, and pricing and reimbursement policies. Additionally, clinical trial delays and regulatory challenges may impact the company's ability to successfully commercialize products.
November 13, 2025
In a significant advancement for the future of Alcohol Use Disorder (AUD) treatment, Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) announced it has received final approval to expand its innovative Phase 1/2a clinical trial at the prestigious Hadassah Medical Center in Jerusalem, Israel. The company, known for pioneering psychedelic-derived therapeutics to address under-treated health issues, is advancing its proprietary MEAI-based oral drug candidate, CMND-100, with promising prospects. Clearmind s Clinical Advancements: A Step Toward New Solutions The inclusion of Hadassah Medical Center in Clearmind s ongoing clinical trial marks a crucial milestone. This renowned medical institution adds significant c...
March 19, 2025
In an ambitious move to enhance the effectiveness of its psychedelic-based treatments, Clearmind Medicine Inc. has announced plans to evaluate the intranasal delivery of its unique psychedelic drug combinations. This strategic initiative is aimed at improving the bioavailability and optimizing the therapeutic effects of their groundbreaking treatments. As the company embarks on this new frontier, it faces the dual challenge of technological innovation and fierce market competition. The Promise of Intranasal DeliveryIntranasal drug delivery is a forward-thinking approach renowned for its potential to offer faster absorption and improved bioavailability compared to traditional oral administration. This method ...
September 16, 2024
Clearmind Medicine: Pioneering Ibogaine Combination Therapy Amid Competitive Market Challenges Clearmind Medicine is a beacon of innovation in the biopharmaceutical industry, yet it faces significant financial headwinds compared to its competitors. In the ever-evolving landscape of biopharmaceutical innovation, Clearmind Medicine Inc. has taken a significant leap forward with its announcement of an international patent application for a pioneering ibogaine combination therapy. Developed in collaboration with SciSparc, this groundbreaking drug treatment aims to enhance safety and efficacy in mental health and addiction care, marking a significant advancement in addressing these persistent healthcare challeng...
June 20, 2024
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentVancouver-based biotech company, Clearmind Medicine Inc. (Nasdaq: CMND), recently made an exciting announcement regarding its future endeavors in the field of mental health treatment. The company has signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, acquiring exclusive global rights to further develop, manufacture, and commercialize novel compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel. These compounds have shown promising potential in treating post-traumatic stress disorder (PTSD) and other mental health...
February 23, 2024
Clearmind Medicine Inc. has recently received approval to commence its Phase I/IIa clinical trial for CMND-100, a unique psychedelic called MEAI, aimed at treating Alcohol Use Disorder (AUD). This groundbreaking development marks the first time that patients with AUD will be offered this proprietary psychedelic treatment. However, the company s financial performance in the third quarter of 2023 has raised concerns due to a net loss despite its competitors experiencing significant revenue growth.Clearmind Medicine Inc., a pharmaceutical company focused on addressing mental health issues, has achieved a significant milestone by gaining approval to begin Phase I/IIa clinical trials for CMND-100. This revolution...
January 16, 2024
Clearmind Medicine Inc., a biotech company dedicated to the discovery and development of innovative psychedelic-derived therapies, recently announced the closure of its registered direct offering, raising approximately $2.4 million in gross proceeds. The company also entered into a simultaneous private placement with institutional investors, further bolstering its financial position. This funding will enable Clearmind Medicine to continue addressing significant unmet medical needs through the advancement of its research and development initiatives.Accelerating Breakthroughs in Psychedelic-Derived Therapeutics:By leveraging the potential of psychedelics, Clearmind Medicine Inc. aims to address major under-tre...
January 11, 2024
Clearmind Medicine Inc., a biotech company with a primary focus on the discovery and development of novel psychedelic-derived therapeutics, recently announced the pricing of its $2.4 million registered direct offering and private placement. The company aims to address major under-treated health problems through innovative solutions. This article delves into the latest development and explores the potential implications for Clearmind Medicine Inc. s future.Clearmind Medicine Inc. s Fundraising EndeavorsClearmind Medicine Inc. secured agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering. Additionally, the company entered into...
Meta Platforms Inc operates as a social media conglomerate, focusing on generating revenue primarily through targeted advertising services across its platforms. Its business model is centered on attracting a vast user base and utilizing user data to enhance ad personalization, creating value for users, advertisers, and the platform itself.
Pasithea Therapeutics Corp's business model revolves around the development and commercialization of therapeutic treatments for sleep disorders and other related conditions.
Professional Diversity Network Inc Share Performance
-98.25%
One Year
Professional Diversity Network Inc
Profile
Professional Diversity Network Inc is a company that operates an online platform which connects diverse professionals with employers seeking to increase diversity and inclusion in their workforce.
Sources:
Clearmind Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Clearmind Medicine Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
